Gefitinib for advanced bronchioloalveolar carcinoma.
- Author:
Xiao-tong ZHANG
1
;
Shu-lan WANG
;
Long-yun LI
Author Information
1. Department of Respiratory Disease, PUMC Hospital, CAMS and PUMC, Beijing 100730, China.
- Publication Type:Case Reports
- MeSH:
Adenocarcinoma, Bronchiolo-Alveolar;
drug therapy;
Aged;
Antineoplastic Agents;
therapeutic use;
Female;
Humans;
Lung Neoplasms;
drug therapy;
Middle Aged;
Quinazolines;
therapeutic use;
Receptor, Epidermal Growth Factor;
antagonists & inhibitors
- From:
Acta Academiae Medicinae Sinicae
2004;26(3):340-343
- CountryChina
- Language:Chinese
-
Abstract:
We described 3 cases of advanced bronchioloalveolar carcinoma (BAC), in whom once-daily treatment with 250 mg Gefitinib (Iressa) demonstrated remarkable antitumor effects. Gefitinib may produce dramatic clinical responses when administered to patients with poor performance status who had received heavy platinum/docetaxel-based prior chemotherapy.
